A Novel Homozygous Y140X Mutation of ISG15 Causes Diverse Type I Interferonopathies in Sibling Patients with Cutaneous Lesions or Recurrent Parenchymal Pneumonia.

Qiling Xu,Wenyan Li,Qian Zhao,Lu Zhao,Ge Lv,Gan Sun,Yelei Gao,Yuan Ding,Zhiyong Zhang,Lina Zhou,Yongwen Chen,Xuemei Tang,Jin Zhu,Xiaodong Zhao,Yunfei An
DOI: https://doi.org/10.1016/j.clim.2023.109844
IF: 10.19
2023-01-01
Clinical Immunology
Abstract:PURPOSE:Interferon-stimulated gene 15 (ISG15) deficiency, a rare human inborn error of immunity characterized by susceptibility to Bacillus Calmette-Guerin (BCG) diseases, neuropathic and dermatological manifestations.METHODS:The clinical and immunological features of two siblings with ISG15 deficiency combined with asymptomatic myeloperoxidase (MPO) mutations were analyzed, and their pathogenesis, as well as target therapeutic candidates, were explored.RESULTS:The manifestation in patient 2 was skin lesions, while those in patient 1 were intracranial calcification and recurrent pneumonia. Whole-exome identified novel, dual mutations in ISG15 and MPO. PBMCs and B cell lines derived from the patients showed hyper-activated JAK/STAT signaling. Normal neutrophil function excluded pathogenicity caused by the MPO mutation. RNA sequencing identified baricitinib as therapeutic candidate.CONCLUSIONS:We report two sibling patients harboring the same novel ISG15 mutation showing diverse clinical features, and one harbored a rare phenotype of pneumonia. These findings expand the clinical spectrum of ISG15 deficiency and identify baricitinib as therapeutic candidate.
What problem does this paper attempt to address?